Last updated 11/09/2023
Monday, November 13
Patent Implications of the Inflation Reduction Act | 3:30 PM - 4:45 PM
Sponsored By: Choate Hall & Stewart LLP
The Inflation Reduction Act (IRA) does not address patents, but its drug pricing provisions are likely to prompt major changes in how patents work in the pharmaceutical industry. This panel will discuss how the IRA may impact IPCC, updates to current IRA-related litigation, and potential impacts in patent litigation strategies.
Moderator:
- Eric Marandett, Co-Chair, IP Litigation, Choate
Speakers:
- Steve Bossone, PhD, SVP, Chief Patent Counsel, Alnylam Pharmaceuticals
- John Delacourt, Deputy General Counsel, BIO
- Anita Spieth, Co-Chair, IP Litigation, Choate
Tuesday, November 14
Impact of AI on IP: Guardian or Terminator | 9:00 AM - 10:15 AM
Sponsored By: McDonnell Boehnen Hulbert & Berghoff LLP
The impact of Artificial Intelligence is being felt across all of society and in numerous sectors, and Intellectual Property has been no exception. This session will examine the evolving impact of AI on the invention creation process, inventorship, and patent procurement and enforcement. The session will also examine how courts and patent offices are dealing with the intersection of AI and IP.
Moderator:
- Don Zuhn, Partner, MBHB
Speakers:
- Brian Cocca, Executive Director, Assistant General Counsel, Patents, Regeneron Pharmaceuticals Inc.
- Jason Derry, Associate General Counsel - Intellectual Property, Synthego
- Aaron Gin, PhD, Partner, MBHB
- Charles Kim, Director of the Office of Petitions, USPTO
From Gilead to Cellect: A Comprehensive Analysis of Key Developments in ODP and Implications for PTA and PTE | 10:30 AM - 11:45 AM
Sponsored by: Fenwick & West LLP
Join us for an in-depth discussion on the recent In re Cellect decision and the implications for Obviousness-type Double Patenting (ODP) on Patent Term Adjustment (PTA) and Patent Term Extensions (PTE). We’ll begin with an insightful overview of the origins and evolution of ODP, highlighting the doctrine’s relationship with PTA and PTE in key cases like Gilead v. Natco and Novartis v. Breckenridge followed by a look at recent case settlements involving double-patenting leading up to the Cellect decision. Finally, we’ll offer guidance on what the ruling means for patent portfolio strategy, prosecution, and litigation moving forward.
Moderator:
- Ryan Johnson, Partner, Litigation, Fenwick
Speakers:
- James Evans, PhD, JD, Senior Director, Assistant General Counsel, Dispute Resolution, Regeneron Pharmaceuticals
- Carl Morales, PhD, Partner, Intellectual Property, Fenwick
- Lulu Wang, PhD, JD, Head of Intellectual Property, Orna Therapeutics
IP Transactions: Peering Through the Looking-Glass Without Falling Down a Rabbit Hole | 1:00 PM - 2:15 PM
Sponsored by: Foley Hoag LLP
This panel will include an interactive discussion among attorneys who have litigated issues arising from IP transactions and in-house IP counsel involved in transactions and will focus on practical tips for balancing litigation risk while getting the deal done. Topics will include case law updates on the scope of the attorney-client privilege, including the common interest privilege, in the context of deals; how to ensure you have standing to enforce the patent rights you licensed or acquired; what to consider in negotiating indemnification and venue selection clauses; and how to mitigate the contamination and disclosures risks to your IP when sharing confidential information during negotiations.
Moderator:
- Barbara Fiacco, Partner, Co-Chair of Intellectual Property Department, and Co-Chair of Patent, Trade Secrets, and Related Rights Litigation Practice, Foley Hoag LLP
Speakers:
- Christine Bellon, Chief Legal Officer, Beam Therapeutics
- Jeremy McKown, Global Patent Head - Innovative Medicine, Johnson & Johnson
- David Pauling, General Counsel, Sutro Biopharma
- Jeremy Younkin, Partner and Co-Chair of Patent, Trade Secrets, and Related Rights Litigation Practice, Foley Hoag LLP
When On-Time is Late: Expediting US and Foreign Issuance | 2:30 PM - 3:45 PM
Sponsored by: McNeill Baur PLLC
Panel will lead a discussion about why, when, and how to expedite US and foreign patent coverage, including PTA and PTE considerations.
Moderator:
- Amelia Feulner Baur, PhD, Founding Partner, McNeill Baur PLLC
Speakers:
- Eyal Barash, Founder, Barash Law LLC
- Deborah Herzfeld, Partner, McNeill Baur PLLC
- Lulu Wang, PhD, JD, Head of Intellectual Property, Orna Therapeutics
Wednesday, November 15
Biosimilars: What We Learned in 2023 | 8:30 AM - 9:45 AM
Sponsored by: Akin Gump Strauss Hauer & Feld LLP
New developments in the last year point the way to interesting strategies for biosimilars cases, including for patent portfolio analysis, patent term planning, timing of litigation, structuring litigation scope, and case resolution. The panel will explore all of this and more.
Speakers:
- Kenneth Dow, JD, SVP, General Counsel, Century Therapeutics
- Matthew Pearson, Partner, Akin Gump
- Jonathan Underwood, Counsel, Akin Gump
The UPC in Action: What Can we Learn From the First Life Science Cases? | 10:00AM - 11:15AM
Sponsored by: df-mp
The Unified Patent Court (UPC) opened its doors for business on June 1, 2023. While many key life science patents have been opted out of the UPC’s jurisdiction, a couple of biotech cases are leading the way in testing this new European litigation forum. The panel will explore what can be learned from these first cases at the UPC, sharing hands-on experiences.
Moderator:
- Sandra Pohlman, Co-Founder and Partner, df-mp
Speakers:
- Elisabeth Greiner, Partner, df-mp
- Henry Gu, Senior Vice President, Intellectual Property, Zentalis Pharmaceuticals
- Daniella Kinkeldey, PhD, Partner, Bird & Bird
